Business Insider3d
Shanghai Henlius Biotech to Vote on Major Merger
Shanghai Henlius Biotech, Inc. Class H (HK:2696) has released an update. Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks Make smarter ...
Business Insider3d
Shanghai Henlius Biotech Moves Toward Privatization
Shanghai Henlius Biotech, Inc. Class H (HK:2696) has released an update. Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks Make smarter ...
GlobalData on MSN4d
Palleon and Shanghai Henlius Biotech link on autoimmune therapy
Palleon Pharmaceuticals and Shanghai Henlius Biotech have entered a licence agreement and partnership for the former’s ...
Shanghai Fosun Pharmaceutical Advances Henlius Merger Plans
Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks ...
Hosted on MSN18d
Shanghai Henlius Biotech Advances in Cancer Treatment
Shanghai Henlius Biotech, Inc. Class H (HK:2696) has released an update. Shanghai Henlius Biotech, Inc. has received approval from China’s National Medical Products Administration to initiate ...
Palleon Pharmaceuticals and Henlius Collaborate to Advance Glycan Editing as a Treatment for Autoimmune Diseases
Palleon Pharmaceuticals, a company pioneering glyco-immunology drug development to treat autoimmune diseases and cancer, today announced a collaboration and license agreement with Shanghai Henlius ...
Yahoo Finance6d
High Growth Tech Stocks Including Shanghai Henlius Biotech
Overview: Shanghai Henlius Biotech, Inc. focuses on the research and development of biologic medicines targeting oncology, autoimmune diseases, and ophthalmic diseases, with a market cap of HK$12. ...
Shanghai Henlius Biotech Announces Merger Vote
Shanghai Henlius Biotech, Inc. Class H (HK:2696) has released an update.Don't Miss Our Christmas Offers:Discover the latest stocks recommended ...